Akums Drugs and Pharmaceuticals Limited — Board Meeting, 08-08-2026: Outcome of Board Meeting

Akums Drugs (AKUMS) board approved Q1FY27 consolidated results: Revenue at ₹1,166.63 Cr, Profit at ₹100.98 Cr. Shareholders approved ₹3/share dividend for FY26. All ₹642.18 Cr IPO proceeds fully utilized. Post-quarter, a subsidiary acquired Oriflame India's manufacturing biz for ₹56.00 Cr, boosting capacity.